<DOC>
	<DOCNO>NCT01187264</DOCNO>
	<brief_summary>In study investigator intend compare efficacy safety two fixed dos weekly oral methotrexate prospective randomize double blind manner patient severe plaque type psoriasis .</brief_summary>
	<brief_title>Dose Ranging Study Compare Efficacy Safety Methotrexate Plaque Type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Patients plaquetype psoriasis 10 % body surface area involvement ( severe psoriasis ) .20 Patients either sex age 1865 year . Females postmenopausal tubectomised complete family size willing maintain contraception 1 month , 1 month completion/stopping treatment negative pregnancy test 2 week start treatment day 2 3 normal menstrual cycle . Males willing maintain contraception 3 month completion/stopping treatment . Pregnant lactating woman . Any abnormality renal function , cardiovascular disease , respiratory disease neuropsychiatric illness . Significant abnormality liver function ( serum bilirubin , AST , ALT , ALP &gt; 1.5 time upper limit normal ) , viral hepatitis cirrhosis . history excessive alcohol consumption . Severe anemia , leucopenia thrombocytopenia . Active infectious disease immune system deficiency include AIDS . history intolerance/hypersensitivity methotrexate . history phototherapy past 6 month . Patients receive systemic treatment psoriasis past 4 week topical treatment past 2 week . Body mass index ( BMI ) &gt; 30 kg/m2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>